

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.419C12APPLICATION NO.  
09/924,400THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

August 7, 2001

GROUP ART UNIT

1631

RECEIVED

OCT 02 2003

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	TECH CENTER SUBCLASS	FILING DATE APPROPRIATE
MKB	AA	5,912,143	06/15/99	Bandman et al.	435	69.1	
	AB	6,329,505	12/11/01	Xu et al.	530	350	
	AC	6,344,550	02/05/02	Frudakis et al.	536	23.5	
	AD	2002/0009738	01/24/02	Houghton et al.	435	6	
	AE	2002/0022248	02/21/02	Xu et al.	435	69.1	
		2002/0051977	05/02/02	Xu et al.	435	6	
		2002/0068285	06/06/02	Frudakis et al.	435	6	
		2002/0165371	11/07/02	Frudakis et al.	536	23.1	
		2002/0183251	12/05/02	Xu et al.	514	12	
		2002/0193296	12/19/02	Xu et al.	514	12	
		2002/0192763	12/2002	Xu et al.	435	69.7	
MKB		2003/0088062	05/08/03	Xu et al.	530	350	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
MKB	AF	EP 1033401 A2	09/06/00	EPO		
	AH	WO 99/31236	06/24/99	WIPO		
	AI	WO 01/51628	07/19/01	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MKB	AK	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3:283-291, April 1993.
	AL	Attwood, T.K., "The Babel of Bioinformatics," <i>Science</i> 290: 471-473, October 20, 2000.
	AM	Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," <i>Adv. Cancer Res.</i> 58:177-210,

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C12	APPLICATION NO. 09/924,400
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE August 7, 2001	GROUP ART UNIT 1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						


## FOREIGN PATENT DOCUMENTS



	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MKS	BC	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>Journal of Cell Biology</i> 111: 2129-2138, November 1990.
	BD	Cawthon et al., "cDNA Sequence and Genomic Structure of <i>EVI2B</i> , a Gene Lying with an Intron of the Neurofibromatosis Type 1 gene," <i>Genomics</i> 9: 446-460, 1991.
	BE	Curti, B.D., "Physical barriers to drug delivery in tumors," <i>Critical Reviews in Oncology/Hematology</i> 14:29-39, 1993.
	BF	Dermer, G.B., "Another Anniversary for the War on Cancer," <i>Bio/Technology</i> 12: 320, March 1994.
	BG	Drexler, H. "Recent Results on the Biology of Hodgkin and Reed-Sternberg cells. II. Continuous Cell Lines," <i>Leukemia and Lymphoma</i> 9: 1-25, 1993.
	BH	Embleton, M.J., "Monoclonal Antibodies to Osteogenic Sarcoma Antigens," in <i>Monoclonal Antibodies and Cancer, Immunology Series</i> 23, Wright, Jr. G.L. (ed.), Marcel Dekker, New York, NY, 1984, pp. 181-207.
	BI	Freshney, R.I., <i>Culture of Animal Cells: A Manual of Basic Technique</i> , Alan R. Liss, Inc., New York, 1983, pp.3-4.
	BJ	GenBank Accession No. AA533501, August 1, 1997.
	BK	GenBank Accession No. AC018804, February 11, 2003.
	BL	GenBank Accession No. AI804733, July 6, 1999.







EXAMINER <i>MKS</i>	DATE CONSIDERED <i>3/12/04</i>
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C12		APPLICATION NO. 09/924,400	
 <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS Tony N. Frudakis et al.		GROUP ART UNIT 1631 RECEIVED	
				FILING DATE August 7, 2001			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	AGING DATE IF APPROPRIATE
	CA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO
	CB						
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>MKB</i>	CC	GenBank Accession No. AQ063365, July 30, 1998.					
	CD	GenBank Accession No. AQ124119, August 31, 1998.					
	CE	Geneseq (Derwent) Accession No. AAV68996, January 22, 1999.					
	CF	Geneseq (Derwent) Accession No. AAL10921, December 7, 2001.					
	CG	Geneseq (Derwent) Accession No. AAL11383, December 7, 2001.					
	CH	Geneseq (Derwent) Accession No. AAL11455, December 7, 2001.					
	CI	Geneseq (Derwent) Accession No. AAL13620, December 7, 2001.					
	CJ	Geneseq (Derwent) Accession No. AAL18685, December 7, 2001.					
	CK	Geneseq (Derwent) Accession No. AAL20282, December 7, 2001.					
	CL	Geneseq (Derwent) Accession No. AAL20354, December 7, 2001.					
EXAMINER <i>MKB</i>				DATE CONSIDERED 3/12/04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C12		APPLICATION NO. 09/924,400	
 <p><b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)</p>				APPLICANTS Tony N. Frudakis et al.		GROUP ART UNIT 1631	
				FILING DATE August 7, 2001			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
DA							
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
DB							
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
MCB	DC	Genseq (Derwent) Accession No. AAL22489, December 7, 2001.					
	DD	Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12): 973-981, 1996.					
	DE	Geysen et al., "Cognitive Features of Continuous Antigenic Determinants," <i>Journal of Molecular Recognition</i> 1(1):32-41, 1988.					
	DF	Gillies and Wesolowski et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibod. Hybridomas</i> 1(1): 47-54, 1990.					
	DG	Harris et al., "Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect," <i>Journal of the American Society of Nephrology</i> 6(4): 1125-1133, October 1995.					
	DH	Hartwell et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs," <i>Science</i> 278: 1064-1068, November 7, 1997.					
	DI	Hsu, T.C., "Karyology of Cells in Culture," in Tissue Culture: Methods and Applications, Kurse, Jr et al. (eds.), Academic Press, New York, 1973, pp . 764-767.					
	DJ	Jain, R. K., "Barriers to Drug Delivery in Solid Tumors," <i>Scientific American</i> 271(1): 58-65, July 1994.					
	DK	Johnstone and Thorpe (eds.), <i>Immunochemistry in Practice</i> , Second Edition, Blackwell Scientific Publications, Oxford England, 1987, pp 49-50.					
	DL	Lazar et al., "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molecular and Cellular Biology</i> 8: 1247-1252, March 1988.					
EXAMINER 				DATE CONSIDERED 3/12/04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

RECEIVED

TECH CENTER 1600/2000

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C12		APPLICATION NO. 09/924,400	
 <p>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>				APPLICANTS Tony N. Frudakis et al.			
				FILING DATE August 7, 2001			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	EB						
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	EC	Russell and Barton, "Structural Features can be Unconserved in Proteins with Similar Folds," <i>J. Mol. Biol.</i> 244: 332-350, 1994.					
	ED	Tao and Morrison, "Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <i>Journal of Immunity</i> 143(8): 2595-2601, October 15, 1989.					
	EE	Venter et al., "Genome sequence analysis: scientific objectives and practical strategies," <i>Trends in Biotechnology</i> 10: 8-11, Jan/Feb 1992.					
	EF	Walter, G., "Production of use of antibodies against synthetic peptides," <i>Journal of Immunological Methods</i> 88: 149-161, 1986.					
	EG	Wei, W.-Z. et al., "Protection Against Mammary Tumor Growth By Vaccination with Full-Length, Modified Human <i>ErbB-2</i> DNA," <i>Int. J. Cancer</i> 81: 748-754, 1999.					
	EH	Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases," <i>Journal of Leukocyte Biology</i> 61: 545-550, May 1997.					
	EI						
	EJ						
	EK						
	EL						
EXAMINER 				DATE CONSIDERED 			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							